The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Paul A. Hamlin, Bruce D. Cheson, Charles Michael Farber, Tatyana Feldman, Timothy S Fenske, Brian T. Hess, James L. Khatcheressian, Carole Brennan Miller, Javier Munoz, Manish R. Patel, Sonali M. Smith, Stephen Douglas Smith, Don A. Stevens, Jing Christine Ye, Andrew Steele, Anjali Pandey, Matt Birrell, Janet Leeds, Greg Coffey, John T Curnutte
Institutions: Memorial Sloan Kettering Cancer Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Morristown Medical Center, Hackensack University Medical Center, Medical College of Wisconsin, Medical University of South Carolina, MUSC Hollings Cancer Center, Virginia Cancer Institute, Saint Agnes Hospital, Banner MD Anderson Cancer Center, Seattle Cancer Care Alliance, University of Washington, University of Chicago, University of Michigan, Portola Pharmaceuticals (United States)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889625195